

Product Data Sheet

Product Name: Bevacizumab vedotin

Cat. No.: GC78797

Chemical Properties

Cas. No.

Formula

M.Wt 149114

Solubility

Storage Store at -80°C, protect from light

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

Bevacizumab vedotin is an antibody-drug conjugate (ADC). Bevacizumab vedotin blocks the VEGF/VEGFR pathway to exert anti-angiogenic effects. Bevacizumab vedotin exhibits anti-proliferative effects on cancer cells, promotes cancer cell apoptosis (Apoptosis), induces cancer cell cycle arrest, and possesses anti-migratory activity against breast cancer cells. Bevacizumab vedotin can be used in research related to glioma, hepatocellular carcinoma, and breast cancer [1].

In Vitro, Bevacizumab vedotin (1 mg; 72-120 h) exhibits high serum stability [1]. Bevacizumab vedotin (30-165 min) rapidly and completely releases its MMAE payload under the mediation of cathepsin

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

B^[1]. Bevacizumab vedotin (0-10 µg/mL; 48 h) potently inhibits the proliferation of U87, HepG2 and MCF-7 cells, with IC₅₀ values of 14.1712 µg/mL, 0.6483 µg/mL and 0.1442 µg/mL, respectively^[1]. Bevacizumab vedotin (1 µg/mL; 48 h) induces apoptosis in U87, HepG2 and MCF-7 cells after 48 h of treatment^[1]. Treatment with Bevacizumab vedotin (0.1-20 µg/mL; 48 h) induces G1-phase cell cycle arrest in U87 and HepG2 cells^[1]. Bevacizumab vedotin (0.01-0.1 µg/mL; 12-48 h) inhibits the migration of MCF-7 cells in a concentration- and time-dependent manner, and downregulates the expression of VEGF-A in MCF-7 cells^[1]. Bevacizumab vedotin (0.1-1 µg/mL; 4-48 h) exhibits anti-angiogenic activity, reduces tube formation (junctions and branches) in HUVECs, downregulates VEGF-A expression, and upregulates VEGFR-2 expression in HUVECs^[1].

References:

[1]. Li Y, et al. Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects. *Bioorg Chem.* 2023;137:106575.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA